Searched for
PATENT TERM EXTENSIONS
Reliance AGM 2026 Key Highlights: From Jio IPO, AI ventures to retail bets, check key announcements by Mukesh AmbaniRIL AGM 2026 Key Highlights: Reliance Industries Chairman Mukesh Ambani unveiled major plans at the company's annual general meeting. Key a...- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- As Indians buy pricier phones on EMI, OneAssist bets big on protection plansAs smartphones become costlier and increasingly financed through EMIs, device damage is emerging as a new source of household financial str...
- India’s next big energy bet may come straight from China’s coal handbookThe Strait of Hormuz closure is impacting Asia's chemical industry, pushing India to emulate China's coal-to-chemicals model for energy and...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Air India embraces AI to enhance ops efficiency, increase revenues, reduce costsAir India is embracing artificial intelligence to transform its operations. The airline is using AI to cut costs, improve customer service ...
- US stock market today: Why Dow Jones futures are falling while S&P 500 and Nasdaq futures surge higher? Here’s how global earnings, AI growth, and defense deals are reshaping US stock futures todayUS stock market today shows a sharp split. Dow Jones futures fall over 120 points. Nasdaq futures jump nearly 1%. S&P 500 futures edge high...
- After tariff wars, Trump is opening a new front in US-China rivalryThe US accuses China of stealing AI intellectual property, escalating the tech rivalry beyond tariffs. This move, potentially impacting chi...
- WTO fails to reach consensus on key e-commerce moratorium, reformsThe WTO ministerial conference in Yaounde concluded without agreement on crucial trade issues. Key among these was the e-commerce import du...
- WTO meet concludes; no consensus on extension of e-commerce duty moratoriumWTO talks: The talks at a WTO meeting in Cameroon were seeking to bridge differences over extending the e-commerce moratorium, and agree to...
- Safeguards for generics in UK FTA: GovtThe India-UK free trade agreement safeguards the interests of the Indian generic drugs industry. It does not allow patent extensions or dat...
- India, UK trade pact does not mandate patent term extensions or data exclusivityThe India-UK free trade agreement safeguards the domestic generic drug industry. It avoids patent term extensions and data exclusivity. Thi...
- US government funding yielded hundreds of patents for China-based researchersThe U.S. Defense Department, NASA, and other agencies funded research resulting in over 1,000 U.S. patents for China-based inventors since ...
- India to resist Japan and South Korea's push for patent legislation at RCEPJapan is pushing for patents to be granted for incremental innovations, even if they don’t show any improved efficacy over an existing inve...
- Japan seeks patent term extension at Regional Comprehensive Economic PartnershipRCEP is a proposed free trade agreement among the 10-member Association of Southeast Asian Nations and Australia, China, India, Japan, Sout...
- Glivec lesson for pharma: Patented drugs must be priced smartlyGlivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40 countries.
- Indian patenting system needs to improve, says WIPO chiefIndian patenting system needs to be improved for faster approvals, N N Prasad, Executive Director, WIPO, said here today.
- Dr Reddy's Lab can Touch 1,950: HSBCHSBC has reiterated its 'Overweight' rating on Dr Reddy's Lab and set a target price of 1,950.
- No changes in Indian patent law for nowThe PMO does not plan to seek any changes in two out of four key controversial provisions of the Indian patent law, which can compromise lo...
Load More
